Inhalation Therapy Nebulizer Market Size Share Analysis 2022-2029

The demand for inhalation therapy nebulizers is driven by the prevalence of various respiratory diseases, particularly asthma, cystic fibrosis, and COPD, in worldwide patient populations. According to recent facts revealed by the World Health Organization, asthma is the most prevalent chronic disease in pediatric populations. Besides, asthma is a global health burden in high-income countries and an economic burden in low- and middle-income people. The substantial mortality associated with asthma is fueling the demand for better aerosol drug delivery devices in the healthcare sector.

Further, the number of chronic obstructive pulmonary disease (COPD) has increased to 251 million in 2016 compared to 65 million in 2005. The rate is anticipated to grow at a notable rate over the coming years.​ The increasing geriatric population around the world is expected to boost the market growth. According to the United States Census Bureau’s Statistics, as of 2017, the total number of people aged between 65 and older surpassed 50 million.

As stated by the United Nations, during 2015-2030, the number of senior persons aged 60 years or worldwide is estimated to grow by 56% (from 901 million to more than 1.4 billion). Therefore, attributing to the fact that asthma is a broadly prevalent disease found in people over age 65, and asthma in older adults can cause serious health issues if not treated accurately, the rising geriatric population is expected to propel the market growth the forecast period.

Moreover, the economic and social commission for Asia and the Pacific (ESCAP) reports that the geriatric population in Asia-Pacific was around 548 million in 2019, accounting for more than half of the world’s total elderly population. It is estimated that, by 2050, Asia-Pacific may account for almost two-thirds of the world’s geriatric population. Hence, because asthma is a widely prevalent disease found in people over age 65, the growing aging population is expected to drive the market growth over the forecast period.

Besides, technological advancements are anticipated to provide market growth. Limitations of traditional treatments, such as the late-onset of action and low efficacy, are projected to encourage nebulizers' development. An increase in awareness about cystic fibrosis in the low- and middle-income, early diagnosis of cystic fibrosis, low cost of a diagnostic test, and well-established health care infrastructure in the region are likely to contribute to the inhalation therapy nebulizer market.

Initiatives such as the “Global Alliance Against Chronic Respiratory Diseases” are likely to improve diagnosis and treatment rates of respiratory disorders, which may, in turn, boost the market for inhalation therapy nebulizers. Besides, factors such as unhealthy diet, overconsumption of tobacco and alcohol, lack of physical activity, and the rising rate of obesity are likely to increase respiratory disorders, which will contribute to market growth over the forecast period.

As the coronavirus disease 2019 (COVID-19) pandemic spreads, it will continue to affect the medical device industry. Inhalation therapy nebulizers are no exception, and the effect on their uptake and adoption will be multifaceted. COVID-19 has highlighted the need for clear and accurate guidance on the use of aerosol-generating procedures, such as nebulization, for the treatment of patients with respiratory diseases with or without COVID-19.

Despite the lack of evidence, there is heightened concern about the potential risk of transmission of SARS-CoV-2 in the form of aerosolized respiratory droplets during the nebulized treatment of patients with COVID-19.  Consequently, the use of metered-dose inhalers (MDIs) has risen considerably as an alternative to nebulized therapy, which has led to inadequate supplies of MDIs in some parts of the world. The Canadian Paediatric Society and the Global Initiative for Asthma have both advised against nebulized treatment unless necessary. The National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) has recommended the continued use of nebulized treatment when applicable.

The Centers for Disease Control and Prevention (CDC) does not advise against nebulized treatment. However, it is categorized as an unknown exposure for healthcare personnel. Thus, there is a concern that healthcare personnel and healthcare institutions will approach the use of nebulizers in their patients with an overabundance of caution based on the lack of evidence.  

As a result of the pandemic, the use of metered-dose inhalers (MDIs) has increased substantially as an alternative to nebulized therapy. This factor is hampering the market growth over the forecast period. Physicians and home-based patients may also misinterpret government recommendations that warn of the possible risk regarding the transmissibility of SARS-CoV-2 by people with suspected COVID-19 who are using nebulized therapy. Therefore, physicians and home-based patients may feel compelled to switch from nebulized treatments to handheld devices. A sudden transition to MDIs may result in unintended consequences for some patients, who may be unable to adequately use their new device or benefit fully from treatment via handheld inhalers.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com